Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2009 by Rabin Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00945386
First received: July 23, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted

July 23, 2009
July 23, 2009
August 2009
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission
The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission

Pediatric patients, during their illness often treated with furosemide (Lasix) continuous drip, often, with dosages above 4-6mg/kg/day (the recommended dose).

This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.

This study will record hearing status, by acoustic emission, of critically ill children, treated with different dosages of furosemide drip.

Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip.

Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
critically ill children in pediatric ICU.
Hearing Status
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
August 2010
Not Provided

Inclusion Criteria:

  • All children admitted to Pediatric ICU who are treated with furosemide continuous drip.

Exclusion Criteria:

  • Children with known hearing abnormalities prior to treatment.
Both
1 Month to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00945386
005418
No
Not Provided
Not Provided
Dr. Elhanan Nahum, Rabin Medical Center
Rabin Medical Center
Not Provided
Study Director: Elhanan Nahum, MD Schneider Children's Hospital
Rabin Medical Center
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP